Cargando…
Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
The introduction of targeted therapy against CD20(+) with the monoclonal antibody rituximab has dramatically improved the survival of B-cell non-Hodgkin lymphoma including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma. Unfortunately, CLL remains incurable with chemoimmunotherapy, wit...
Autores principales: | Cerquozzi, Sonia, Owen, Carolyn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337412/ https://www.ncbi.nlm.nih.gov/pubmed/25733804 http://dx.doi.org/10.2147/BTT.S61600 |
Ejemplares similares
-
Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia
por: Seiter, Karen, et al.
Publicado: (2015) -
New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab
por: Shah, Arpita
Publicado: (2015) -
Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
por: Smolej, Lukáš
Publicado: (2014) -
Clinical application of obinutuzumab for treating chronic lymphocytic leukemia
por: Luan, Chunyan, et al.
Publicado: (2019) -
Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia
por: Hill, Brian T, et al.
Publicado: (2015)